ArticleCureus2025
High-Density Glasses in Blepharospasm: Influence of Migraine and Early Morning Effects.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photophobia and somatosensory disorders in patients with benign essential blepharospasm (BEB) are caused by the accumulation of light input to the brain, resulting in persistent eye-opening difficulties. Consecutive patients with photophobia and photosensitivity due to BEB were recruited. The patients were asked to participate in a trial using high-density glasses, with only 1.5% visible light transmittance, produced by Tokai Optical Co. Ltd. (HD glass®) (Aichi, Japan). Patients were instructed to wear glasses 2-3 times per day for 20 min or more in a dimly lit room every day for at least two months. Patients answered a questionnaire on the effects of wearing glasses whilst wearing them (during), approximately 30 min after removing the glasses (after), and two months after the self-trial (two-month). A total of 61 patients (52 women and 9 men) aged 21-81 (51.5±17.4) years were recruited. Early morning effects were identified in 39 patients (64.0%), and a present or previous history of migraine was reported in 29 patients (47.5%). More than half of the patients eventually reported improvement. The improvement rate was significantly higher at all three time points (during, after, and two months) in the group with early morning effects than in the group without early morning effects. Migraines, which are often associated with photophobia, may be a risk factor for BEB. This trial, using high-density glasses to inhibit light input to the brain, proved beneficial, particularly in patients with BEB and early morning effects, increasing their quality of life after two months. However, controlled trials are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.